Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
10
×
life sciences
national blog main
pfizer
10
×
national
national top stories
san diego blog main
san diego top stories
san francisco blog main
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bristol-myers squibb
startups
abbvie
cancer
medicare
merck
novartis
president trump
alzheimer's disease
astrazeneca
cancer immunotherapy
deals
What
drug
10
×
bio
roundup
ceo
prices
week
acquisitions
alzheimer’s
approved
biggest
biotech
companies
medical
new
news
patients
pfizer
pharmaceutical
plan
research
today
year
adu
advantages
albert
alex
announced
annual
assessed
athena
attention
away
bar
beats
bids
biogen
bourla
bringing
brings
build
Language
unset
unknown
Current search:
drug
×
biotech
×
pfizer
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Pfizer Taps Insilico Medicine to Use AI for Drug Target Discovery
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push